MRI-guided Bone Marrow Biopsies of Advanced CaP Patients

Dana-Farber Cancer Institute1 site in 1 country20 target enrollmentJuly 2001

ConditionsProstate Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: Dana-Farber Cancer Institute
Enrollment: 20
Locations: 1
Primary Endpoint: To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to target lesions of the prostate in the bone and to biopsy these lesions using MRI to identify the areas.

Detailed Description

* This study involves a one-time, MRI-guided bone marrow biopsy. Prior to this procedure, patients will need to have a bone scan performed within the last three months and a PSA blood test drawn within one month of registration to the study. * Patients are also required to participate in the DFCI research study "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer".

Registry

clinicaltrials.gov

Start Date

July 2001

End Date

January 2006

Last Updated

16 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

•Histologic diagnosis of prostate cancer
•Bone scan consistent with or suspicious of metastatic prostate cancer within last three months
•Platelet count \> 50,000/ul
•PT and aPTT \< 1.5 x control
•At least one week removed from taking aspirin or coumadin
•Currently participating in protocol "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer"

Exclusion Criteria

•Devices incompatible to MR studies (e.g. pacemakers, ear implants, etc.)

Outcomes

Primary Outcomes

To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.

Secondary Outcomes

To evaluate the sensitivity of radiographic bone marrow changes detected by MRI for prostate cancer, as determined by the pathologic findings from bone marrow biopsy.